# EDGAR Filing Document

**Accession Number:** 0000086115
**File Stem:** 0001437749-23-005972
**Filing Date:** 2023-3
**Character Count:** 25158
**Document Hash:** 73846607fe3220dfc66532a053198db5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-005972.hdr.sgml**: 20230309

**ACCESSION NUMBER**: 0001437749-23-005972

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230309

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230309

**DATE AS OF CHANGE**: 20230309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SAFEGUARD SCIENTIFICS INC
- **CENTRAL INDEX KEY:** 0000086115
- **STANDARD INDUSTRIAL CLASSIFICATION:** INVESTORS, NEC [6799]
- **IRS NUMBER:** 231609753
- **STATE OF INCORPORATION:** PA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05620
- **FILM NUMBER:** 23719961

**BUSINESS ADDRESS:**
- **STREET 1:** 150 NORTH RADNOR-CHESTER ROAD
- **STREET 2:** SUITE F-200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 610 293 0600

**MAIL ADDRESS:**
- **STREET 1:** 150 NORTH RADNOR-CHESTER ROAD
- **STREET 2:** SUITE F-200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SAFEGUARD INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19810525

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SAFEGUARD CORP
- **DATE OF NAME CHANGE:** 19690521

sfe20230308_8k.htm

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM **8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 9, 2023**

**Safeguard Scientifics, Inc.**

(Exact Name of registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Pennsylvania** | **1-5620** | **23-1609753** |
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | &nbsp;&nbsp;&nbsp;&nbsp; (IRS Employer ID No.) |

---

---

| | |
|:---|:---|
| **150 N. Radnor Chester Rd., STE F-200**<br> **Radnor, **PA** | **19087** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **610-**293-0600**

**Not applicable**

------

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock ($.10 par value) | SFE | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**ITEM 2.02. Results of Operations and Financial Condition.**

On March 9, 2023 Safeguard Scientifics, Inc. (the "Company") issued a press release setting forth the Company's financial information for the three months and year ended December 31, 2022. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**ITEM 9.01. Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| 99.1 | [Press Release of Safeguard Scientifics, Inc. dated March 9, 2023](ex_485968.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **Safeguard Scientifics, Inc.** |
| Date: March 9, 2023 | <u>/s/ G. Matthew Barnard</u> |
|  | Name: G. Matthew Barnard |
|  | Title: General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

![a01.jpg](a01.jpg)

**SAFEGUARD SCIENTIFICS ANNOUNCES FOURTH QUARTER AND YEAR END 2022 FINANCIAL RESULTS**

***Conference call and webcast on March 9, 2023 at 5 p.m. ET***

**Radnor, PA, March 9, 2023** — <u>Safeguard Scientifics, Inc.</u> (NASDAQ: SFE) ("Safeguard" or the "Company") today announced financial results for the three months and year ended December 31, 2022.

**2022 HIGHLIGHTS**

● Exits & Deployments

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o During the fourth quarter, Safeguard funded convertible loans of $0.5 million to meQuilibrium and $0.1 million from its subordinated line of credit to Trice Medical. Safeguard also funded an additional $0.25 million to Trice subsequent to the year-end pursuant to the same arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Safeguard's annual deployments totaled $5.7 million, as compared to the full year 2022 estimated deployments of $5 million to $9 million.

● Safeguard Company Performance

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The aggregate trailing twelve-month revenues ending September 30, 2022 for eight of Safeguard's companies, which excludes Other Ownership Interests, was $141 million, an increase of 8.7% from the comparable prior period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Safeguard's 1.3 million shares of Bright Health Group declined $0.5 million in value during the fourth quarter and $3.7 million for the 2022 annual period, resulting in a year-end value of $0.9 million.

● Capital Return

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o During the fourth quarter, Safeguard repurchased 257,946 shares on the open market for $0.9 million at an average price of $3.41 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o For the year ended December 31, 2022, Safeguard repurchased 711,481 shares on the open market for $2.9 million at an average price of $4.13 per share under a previously authorized $3 million share repurchase plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o In January 2023, the remaining amount authorized under the $3 million plan was purchased through open market transactions resulting in an aggregate of 736,577 shares being repurchased at an average price of $4.09 per share from March 2022 through January 2023.

● Financial Results

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Cash, cash equivalents, restricted cash and marketable securities totaled $19.3 million at December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The carrying value of the Company's ownership interests totaled $15.4 million at December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Net loss for the three months ended December 31, 2022 was $4.9 million, or $0.30 per share, compared with a net loss of $8.6 million, or $0.51 per share, for the same period in 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share, compared with net income of $27.0 million, or $1.36 per share, for the same period of 2021.

● Operating Costs

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Safeguard continued to reduce its operating costs. General and administrative expenses totaled $1.0 million for the fourth quarter as compared to $1.1 million for the comparable quarter of 2021. General and administrative expenses totaled $4.8 million and $7.2 million for the years ended December 31, 2022 and 2021, respectively, a 33% annual decline.

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **1 of 7** |

---

------

![a01.jpg](a01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Safeguard also continued to lower its corporate expenses<sup>1</sup>, which totaled $0.7 million for the fourth quarter of 2022, as compared to $0.8 million for the comparable period of 2021, a 12.5% decline. Corporate expenses totaled $3.2 million and $3.9 million for the years ended December 31, 2022 and 2021, respectively, a 17.9% annual decline.

● Outlook

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Safeguard expects follow-on deployments for its remaining ownership interests for 2023 to be in a range of $4 million to $6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Safeguard expects to continue to closely manage corporate expenses in 2023 and has established a target of $3.0 to $3.2 million for the year, which continue to be exclusive of severance or transaction related expenses.

"The deteriorating business and capital raising environment noted last quarter has continued to impact many of Safeguard's companies, with some lagging their operating plans and others experiencing liquidity challenges. While we are continuing to support our companies, we are considering additional actions to either participate in financing transactions that we view as opportunistic and attractive or, to be significantly diluted by those transactions if completed without our participation. We also continue to work with our financial advisor Houlihan Lokey as we evaluate strategic transactions for Safeguard that could yield greater value to our shareholders than an orderly run-off of the portfolio. In all cases, we remain committed to seeking a path that maximizes shareholder value." said Eric C. Salzman, Chief Executive Officer.

------

<sup>1</sup> Corporate expenses are general and administrative expenses excluding depreciation, severance, stock-based compensation and other non-recurring items. See full reconciliation in the financial section of this statement.

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **2 of 7** |

---

------

![a01.jpg](a01.jpg)

**OWNERSHIP INTERESTS AT DECEMBER 31, 2022**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Companies** | **Category** | **Acquisition Year** | **Primary**<br> **Ownership%** | **Fully Diluted**<br> **Ownership%**<br> **<sup>\*\*</sup>** | ***Carrying*** <br> ***Value***<br> *(in millions)* | ***Cost***<br> *(in millions)* |
|  | **Revenue of $5 million to $10 million**  | **Revenue of $5 million to $10 million**  | **Revenue of $5 million to $10 million**  | **Revenue of $5 million to $10 million**  | **Revenue of $5 million to $10 million**  | **Revenue of $5 million to $10 million**  |
| Moxe | Healthcare | 2016 | 19.3% | 18.2% | 7.2 | 7.5 |
|  | **Revenue of $10 million to $20 million**  | **Revenue of $10 million to $20 million**  | **Revenue of $10 million to $20 million**  | **Revenue of $10 million to $20 million**  | **Revenue of $10 million to $20 million**  | **Revenue of $10 million to $20 million**  |
| Clutch Holdings, Inc. | Digital Media | 2013 | 41.7% | 33.3% | 3.0 | 18.3 |
| InfoBionic, Inc. | Healthcare | 2014 | 25.2% | 22.1% |  | 22.0 |
| meQuilibrium | Healthcare | 2015 | 31.3% | 22.1% |  | 14.5 |
| Syapse, Inc. | Healthcare | 2014 | 11.0% | 8.6% | 1.5 | 26.6 |
|  | **Revenue of $20 million to $30 million**  | **Revenue of $20 million to $30 million**  | **Revenue of $20 million to $30 million**  | **Revenue of $20 million to $30 million**  | **Revenue of $20 million to $30 million**  | **Revenue of $20 million to $30 million**  |
| Aktana, Inc. | Healthcare | 2016 | 13.6% | 11.5% |  | 15.9 |
| Prognos Health, Inc. | Healthcare | 2011 | 28.4% | 24.3% | 1.5 | 14.6 |
| Trice Medical + | Healthcare | 2014 | 11.6% | 8.6% |  | 12.0 |
|  | **Other Ownership Interests** | **Other Ownership Interests** | **Other Ownership Interests** | **Other Ownership Interests** | **Other Ownership Interests** | **Other Ownership Interests** |
| Bright Health Group | Healthcare | 2021 |  |  | 0.9 |  |
| All others | Various | Various |  |  | 1.3 | 19.7 |
|  |  |  |  | TOTAL: | $15.4 | $151.1 |

---

+ Carrying value does not include amounts representing our share of the entities' losses which were funded subsequent to the quarter and are reflected in Accrued expenses.

\*\* Based on information provided by each respective company. Assumes the conversion or exercise of all currently outstanding securities including the issuance of all shares available under authorized employee equity programs. Does not reflect liquidation preferences, priority payments, proceeds from option and/or warrant exercises or other company-specific transaction-related obligations in a liquidation or exit transaction.

**CONFERENCE CALL AND WEBCAST DETAILS** 

*Please call 10-15 minutes prior to the call to register.*

**Date:** March 9, 2023

**Time:** 5:00 p.m. ET

**Webcast:** <u>https://www.webcast-eqs.com/register/safeguardscientifics032023_en/en</u>

**Live Number:** 877-407-1878

**Speakers:** Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

**Format:** Discussion of the quarter's financial results followed by Q&A

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **3 of 7** |

---

------

![a01.jpg](a01.jpg)

The replay will be available at Safeguard.com's investor relations site under "Past events". For more information, please contact IR@safeguard.com.

**About Safeguard Scientifics** 

Historically, Safeguard Scientifics has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. Safeguard is currently pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value. For more information, please visit <u>www.safeguard.com</u>.

**Forward-Looking Statements**

*Except for the historical information and discussions contained herein, statements contained in this release may constitute* "*forward-looking statements*" *within the meaning of the federal securities laws. Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguard*'*s ability to maximize the value of monetization opportunities of its ownership interests and drive total shareholder returns, Safeguard*'*s initiatives, including, without limitation, taken or contemplated to enhance and unlock value for all of its shareholders, Safeguard*'*s efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguard*'*s ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguard*'*s management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguard*'*s strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguard*'*s projections regarding the reduction in its ongoing operating expenses, Safeguard*'*s projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our companies may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of our publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, the Company*'*s past operational and financial performance should not be relied on as an indication of future performance. Further information on the above risk factors and other potential factors that could affect our future business, operating results and financial condition is included in our Annual Report on Form 10-K for the year ended December 31, 2021 and other periodic filings with the Securities and Exchange Commission, including risks under the heading* "*Risk Factors.*" *The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.*

###

**SAFEGUARD CONTACT:** 

Mark Herndon

Chief Financial Officer

(610) 975-4913

mherndon@safeguard.com

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **4 of 7** |

---

------

![a01.jpg](a01.jpg)

**Safeguard Scientifics, Inc.**

**Condensed Consolidated Balance Sheets**

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | December 31, 2022 | December 31, 2021 |
| **Assets** |  |  |
| Cash, cash equivalents, restricted cash and marketable securities | $19312 | $24764 |
| Ownership interests | 860 | 4549 |
| Other current assets | 1251 | 965 |
| Total current assets | 21423 | 30278 |
| Ownership interests in and advances | 14545 | 21972 |
| Other assets | 1724 | 1778 |
| **Total Assets** | $37692 | $54028 |
| **Liabilities and Equity** |  |  |
| Other current liabilities | $1817 | $1734 |
| Total current liabilities | 1817 | 1734 |
| Lease liability - non-current | 1249 | 1678 |
| Other long-term liabilities | 50 | 50 |
| Total equity | 34576 | 50566 |
| **Total Liabilities and Equity** | $37692 | $54028 |

---

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **5 of 7** |

---

------

![a01.jpg](a01.jpg)

**Safeguard Scientifics, Inc.**

**Condensed Consolidated Statements of Operations**

**(in thousands, except per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended | Three Months Ended | Twelve Months Ended | Twelve Months Ended |
|  | December 31, | December 31, | December 31, | December 31, |
|  | 2022 | 2021 | 2022 | 2021 |
| Operating expenses | $1035 | $1135 | $4775 | $7153 |
| Operating loss | (1035) | (1135) | (4775) | (7153) |
| Other income (loss), net | (318) | (5992) | (3297) | 22035 |
| Interest, net | 318 | 79 | 794 | 276 |
| Equity income (loss), net | (3838) | (1586) | (6985) | 11846 |
| Net income (loss) before income taxes | (4873) | (8634) | (14263) | 27004 |
| Income tax benefit (expense) |  |  |  |  |
| Net income (loss) | $(4873) | $(8634) | $(14263) | $27004 |
| Net income (loss) per share: |  |  |  |  |
| Basic | $(0.30) | $(0.51) | $(0.87) | $1.36 |
| Diluted | $(0.30) | $(0.51) | $(0.87) | $1.36 |
| Weighted average shares used in computing income (loss) per share: |  |  |  |  |
| Basic | 16134 | 16798 | 16337 | 19827 |
| Diluted | 16134 | 16798 | 16337 | 19827 |

---

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **6 of 7** |

---

------

![a01.jpg](a01.jpg)

**Safeguard Scientifics, Inc.**

**Financial Data**

**(in thousands)**

**<u>Additional Financial Information</u>**

**<u>Non-GAAP Measures</u>**

In discussing financial results and guidance, the Company refers to the measure "corporate expenses" which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We have defined corporate expenses as general and administrative costs excluding stock based compensation, severance costs, and non-recurring items and other. Non-recurring items and other includes accruals related to the Company's LTIP plan that will not be paid until reaching a specified threshold within that plan as well as costs incurred for exploring strategic alternatives. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends and provides additional transparency on how we evaluate our cost structure. We also believe presenting this measure allows investors to view our performance using the same measure that we use in evaluating our performance and trends.

**Corporate expenses reconciliation:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three Months Ended | Three Months Ended | Twelve Months Ended | Twelve Months Ended |
|  | December 31, | December 31, | December 31, | December 31, |
|  | 2022 | 2021 | 2022 | 2021 |
| Corporate expenses | $722 | $825 | $3172 | $3865 |
| Stock based compensation | 309 | 310 | 1445 | 1779 |
| Severance costs |  |  |  | 774 |
| Non-recurring items and other | 4 |  | 158 | 735 |
| General and administrative expenses | $1035 | $1135 | $4775 | $7153 |

---

---

| | | |
|:---|:---|:---|
| **www.safeguard.com** |© 2023 Safeguard Scientifics, Inc. All rights reserved. | **7 of 7** |

---